Compare Quest Diagnostics Inc (DGX) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nano Dimension Ltd - ADR — how do they compare? Quest Diagnostics Inc trades at $205.04 (market cap $22.80B), while Nano Dimension Ltd - ADR trades at $1.5 (market cap $314.71M). The key difference: Quest Diagnostics Inc is far larger — about 72.4× Nano Dimension Ltd - ADR's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| DGX | NNDM | |
|---|---|---|
Market Cap | $22.80B | $314.71M |
Sector | Health | Technology |
52-Week High | $216.02 | $2.14 |
52-Week Low | $166.42 | $1.21 |
Enterprise Value | $28.82B | -$94.63M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Nano Dimension (NNDM) trades at $1.48, down 1.33% with a bearish technical signal. The company reported Q1 2026 revenue of $102.44M but a net loss of -$293.30M, reflecting a -286.72% margin. Cash burn remains high at -$101.28M from operations. Recent news highlights board disputes with shareholder Murchinson and a proposed merger with Infinite Epigenetics, creating uncertainty.
The outlook is challenged by persistent losses and negative cash flow, though the P/B of 0.64 suggests undervaluation. Risks include execution on strategic plans and shareholder activism. Analyst sentiment is cautious given the lack of profitability and ongoing corporate governance issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
